Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/21638 |
Resumo: | Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second generation tyrosine kinase inhibitors. Furthermore, responses are not sustained in a number of patients, and it is yet unclear whether the inhibitors can be safely discontinued in patients who achieve long-term remission. The emergence of resistance to second generation tyrosine kinase inhibitors has become a significant problem that led to extensive studies on the causal mechanisms. This review will describe our current state of knowledge on why and how chronic myeloid leukaemia cells can develop resistance to second generation tyrosine kinase inhibitors. |
id |
RCAP_30dcd7b80046442b991c384be4535438 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/21638 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABLMechanisms of Resistance to BCR-ABL Kinase InhibitorsIMATINIB MESYLATECML CELLSCHRONIC MYELOID-LEUKEMIAPHILADELPHIA-POSITIVE PATIENTSDrug Resistance, NeoplasmSTEM-CELLSProtein Kinase InhibitorsDOMAIN MUTATIONSImatinibLOW OCT-1 ACTIVITYTYROSINE KINASEACUTE LYMPHOBLASTIC-LEUKEMIACHRONIC MYELOGENOUS LEUKEMIALeukemia, Myelogenous, Chronic, BCR-ABL PositiveSince the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second generation tyrosine kinase inhibitors. Furthermore, responses are not sustained in a number of patients, and it is yet unclear whether the inhibitors can be safely discontinued in patients who achieve long-term remission. The emergence of resistance to second generation tyrosine kinase inhibitors has become a significant problem that led to extensive studies on the causal mechanisms. This review will describe our current state of knowledge on why and how chronic myeloid leukaemia cells can develop resistance to second generation tyrosine kinase inhibitors.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNGomes da Silva, Maria2017-06-21T22:00:39Z2013-072013-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article7application/pdfhttp://hdl.handle.net/10362/21638por1646-0758PURE: 236033info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:08:31Zoai:run.unl.pt:10362/21638Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:26:54.222762Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL Mechanisms of Resistance to BCR-ABL Kinase Inhibitors |
title |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
spellingShingle |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL Gomes da Silva, Maria IMATINIB MESYLATE CML CELLS CHRONIC MYELOID-LEUKEMIA PHILADELPHIA-POSITIVE PATIENTS Drug Resistance, Neoplasm STEM-CELLS Protein Kinase Inhibitors DOMAIN MUTATIONS Imatinib LOW OCT-1 ACTIVITY TYROSINE KINASE ACUTE LYMPHOBLASTIC-LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
title_short |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
title_full |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
title_fullStr |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
title_full_unstemmed |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
title_sort |
Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL |
author |
Gomes da Silva, Maria |
author_facet |
Gomes da Silva, Maria |
author_role |
author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
dc.contributor.author.fl_str_mv |
Gomes da Silva, Maria |
dc.subject.por.fl_str_mv |
IMATINIB MESYLATE CML CELLS CHRONIC MYELOID-LEUKEMIA PHILADELPHIA-POSITIVE PATIENTS Drug Resistance, Neoplasm STEM-CELLS Protein Kinase Inhibitors DOMAIN MUTATIONS Imatinib LOW OCT-1 ACTIVITY TYROSINE KINASE ACUTE LYMPHOBLASTIC-LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
topic |
IMATINIB MESYLATE CML CELLS CHRONIC MYELOID-LEUKEMIA PHILADELPHIA-POSITIVE PATIENTS Drug Resistance, Neoplasm STEM-CELLS Protein Kinase Inhibitors DOMAIN MUTATIONS Imatinib LOW OCT-1 ACTIVITY TYROSINE KINASE ACUTE LYMPHOBLASTIC-LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
description |
Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second generation tyrosine kinase inhibitors. Furthermore, responses are not sustained in a number of patients, and it is yet unclear whether the inhibitors can be safely discontinued in patients who achieve long-term remission. The emergence of resistance to second generation tyrosine kinase inhibitors has become a significant problem that led to extensive studies on the causal mechanisms. This review will describe our current state of knowledge on why and how chronic myeloid leukaemia cells can develop resistance to second generation tyrosine kinase inhibitors. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-07 2013-07-01T00:00:00Z 2017-06-21T22:00:39Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/21638 |
url |
http://hdl.handle.net/10362/21638 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
1646-0758 PURE: 236033 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
7 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137898331635712 |